PDK4 and metabolic disease: Moreover, miR-33 and miR-122, which are commonly altered in metabolic disorders, have been demonstrated to directly target PDK4 in the macrophages to promote cholesterol efflux and reduce atherosclerosis (179) and in the CD133 (+) hepatocellular cancer stem cells (180), respectively.